Junevity raised $10M in seed funding led by Goldcrest Capital and Godfrey Capital to enhance its RESET platform for developing cell reset therapeutics for longevity.
Junevity raised $10M in seed funding led by Goldcrest Capital and Godfrey Capital to enhance its RESET platform for developing cell reset therapeutics for longevity.
02/13/25, 1:03 PM
Location
san franciscoMoney raised
$10 million
Industry
genetics
therapeutics
biotechnology
health care
Round Type
seed
Investors
Godfrey Capital, Goldcrest Capital
Junevity, a biotechnology company focused on extending lifespan and healthspan, announced $10 million in seed funding. The funding will be used to enhance the RESET platform and develop therapeutic candidates targeting Type 2 diabetes, obesity, and frailty.
Company Info
Location
san francisco, california, united states
Additional Info
Junevity is a longevity biotechnology company developing Cell Reset therapeutics. The RESET Platform is the first to use large-scale human data and AI to develop novel siRNA therapeutics targeting transcription factors. Founded out of UCSF in 2023, Junevity’s mission is to extend human lifespan and healthspan.